Cargando…

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis

Detalles Bibliográficos
Autores principales:	Nguyen, Dao X., Cotton, Alice, Attipoe, Laura, Ciurtin, Coziana, Doré, Caroline J., Ehrenstein, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mosby 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127034/ https://www.ncbi.nlm.nih.gov/pubmed/29935955 http://dx.doi.org/10.1016/j.jaci.2018.04.026

Ejemplares similares

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis
por: Nguyen, Dao Xuan, et al.
Publicado: (2016)

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
por: Choida, Varvara, et al.
Publicado: (2021)

Ultrasound-detected subclinical inflammation was better reflected by the disease activity score (DAS-28) in patients with suspicion of inflammatory arthritis compared to established rheumatoid arthritis
por: Ciurtin, Coziana, et al.
Publicado: (2016)

Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis
por: McGovern, Jenny, et al.
Publicado: (2012)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Real benefits of ultrasound evaluation of hand and foot synovitis for better characterisation of the disease activity in rheumatoid arthritis
por: Ciurtin, Coziana, et al.
Publicado: (2019)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Regulatory T cells enhance Th17 migration in psoriatic arthritis which is reversed by anti-TNF
por: Nguyen, Dao X., et al.
Publicado: (2021)

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
por: Elyoussfi, Sarah, et al.
Publicado: (2016)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Successful Treatment of Pseudoseptic Arthritis Contained Massive Purulent Fluid with Adalimumab in Rheumatoid Arthritis
por: Chung, Chong Hyuk, et al.
Publicado: (2020)

Cells of the synovium in rheumatoid arthritis. B cells
por: Mauri, Claudia, et al.
Publicado: (2007)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
por: Kobak, Senol, et al.
Publicado: (2014)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
por: Gissel, C., et al.
Publicado: (2017)

Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices
por: Sakthiswary, R., et al.
Publicado: (2012)

Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia
por: Deakin, Claire T., et al.
Publicado: (2023)

Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
por: Ehrenstein, Michael R., et al.
Publicado: (2004)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β
por: Nadkarni, Suchita, et al.
Publicado: (2007)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis
por: Dias, Olívia Meira, et al.
Publicado: (2014)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis
por: Bergström, Ulf, et al.
Publicado: (2018)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
por: Lee, Myeung-su, et al.
Publicado: (2021)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ouqdr40lcppknom5a7c0a789lj